IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Health is not a hoax: The Power of Legislation & Collaboration in Fighting Fake Medicines
In this year’s Fight the Fakes week, IFPMA will partner with its Africa-based sister associations to facilitate a discussion on the importance of multi-stakeholder collaboration and appropriate legislative frameworks in curbing the threat of substandard and falsified medicines.
Read More
subtopics
Policy Perspectives from the Innovative Biopharmaceutical Industry
Together with the global health community the biopharmaceutical industry is committed to improving pandemic preparedness for the future.
Read More
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
#TeamVaccines campaign
The world doesn’t just need COVID-19 vaccines. We need people around the world to feel confident in getting them, when it’s their turn. This campaign is an opportunity for all of us to help spread confidence and trust in the vaccines! Join #TeamVaccines now!
#TeamVaccines
resources
Position Papers
Call to Action On Routine and Life-Course Immunization in the Context of the COVID-19 Pandemic
Life-course immunization can contribute to healthier, more productive, and longer lives, which enhances the sustainability of healthcare systems
Read More
The African Medicines Agency
AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.
Read More
AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training here
Previous
Next
IFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Inventing Medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Previous
Next
FEATURED RESOURCES : Infographics
IFPMA_HPP_Why is flu vaccination so important during the COVID-19 pandemic_Infographic
Read More
FEATURED RESOURCES : News Releases
This month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity. At current production rates, swiftly rolling out vaccines to those who still need them...
Read More
FEATURED RESOURCES : Statements
Innovative biopharmaceutical companies are at the forefront of the response to the pandemic; not least by developing and manufacturing COVID-19 vaccines in record time. Our industry joins today’s global summit to demonstrate our commitment towards working with governments and global health partners to align on a common vision to expand...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MORE
Our Blog
1 Dec 2021
By Greg Perry
This World AIDS Day, we mark 40 years since the first HIV case was identified. While there is much to reflect on, the most important takeaway is that there is still further to go to prevent new infections and treat the millions of people living with HIV/AIDS today. HIV has been a disease with tragic consequences on too many lives and livelihoods around the world...
Read More
25 Nov 2021
By James Anderson
This op-ed was originally published on Pharma Boardroom on 25 November 2021. The World Health Assembly Special Session on a Pandemic Treaty, which will convene health ministries from around the world in Geneva next week, offers a unique opportunity to take a look back and share some important lessons learnt from fighting the COVID-19 pandemic. James Anderson, Executive Director, Global Health, at IFPMA, lays out...
Read More
18 Nov 2021
By Luka Šrot & Muhammad Ibrahim Khan Luka Šrot & Muhammad Ibrahim Khan
Sometimes dubbed the “silent pandemic,” Antimicrobial Resistance (AMR) is a natural phenomenon that occurs when microorganisms such as bacteria adapt after repeated exposure to antibiotics, rendering treatments ineffective. It has been at the top of the global health agenda for many years, and young professionals in healthcare are acutely aware of it. Health professional networks worldwide are mobilizing themselves through different avenues in an attempt...
Read More
Previous
Next
